IOL Chemicals Announces ₹495 Cr Capex for Capacity Expansion and Business Diversification
IOL Chemicals & Pharmaceuticals Ltd · Others (Uncategorized) · 09 Sept 2026, 8:03 pm
IOL Chemicals Announces ₹495 Cr Capex for Capacity Expansion and Business Diversification IOL Chemicals and Pharmaceuticals Limited announced capex initiatives totaling ~₹495 Cr, funded entirely via internal accruals. The company is expanding its backward-integrated Ibuprofen capacity at Barnala from 12,000 MTPA to 18,000 MTPA with a ₹350 Cr outlay, target commercialization by Dec'27. Additionally, it diversified into pharma formulations CDMO via a 1,500 million tablets/annum facility (₹110 Cr capex) with Hungary GMP approval, operational in Q3 FY'27. It also committed ₹35 Cr for a dedicated specialty chemicals tolling facility for a global client, commercializing in Q3 FY'27.
Original exchange filing (PDF)
More announcements from IOL Chemicals & Pharmaceuticals Ltd
- Clarification on increase in Volume · 11 Nov 2026
- The Exchange has sought clarification from IOL Chemicals & Pharmaceuticals Ltd on November 11, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited. · 11 Nov 2026
- Transcript of Earning Call on the Q2 & H1 FY27 Financial Results · 05 Nov 2026
- Audio Recording of Earnings Call on the Q2 & H1 FY 27 Financial Results · 02 Nov 2026
- Investor Presentation- Q2 & H1 FY27 · 02 Nov 2026
- Press Release · 31 Oct 2026
- Outcome of the Board Meeting and submission of Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2026 · 30 Oct 2026
- Submission of Financial Results · 30 Oct 2026
